Summary
Stryker Corporation reported robust financial results for the second quarter and first half of 2008, demonstrating strong top-line growth and improved profitability. Net sales increased by 17% in the second quarter and 16% for the first half, driven by strong performance in both the Orthopaedic Implants and MedSurg Equipment segments, with particular strength noted in knee, trauma, and spinal implant systems, as well as surgical equipment and patient handling solutions. The company also saw significant growth in its international markets. Profitability also improved, with net earnings from continuing operations rising 27% in the second quarter and 24% for the first half. Diluted EPS from continuing operations grew to $0.73 and $1.43 for the respective periods. Management expressed optimism about the company's outlook for the remainder of 2008, projecting a 22% increase in diluted EPS. The company maintains a strong balance sheet with ample liquidity and borrowing capacity to support its growth initiatives, despite some investments in auction-rate securities facing liquidity challenges.
Financial Highlights
26 data points| Revenue | $1.71B |
| Cost of Revenue | $533.20M |
| Gross Profit | $1.18B |
| R&D Expenses | $90.30M |
| SG&A Expenses | $678.20M |
| Operating Expenses | $778.50M |
| Operating Income | $400.90M |
| Net Income | $305.80M |
| EPS (Basic) | $0.74 |
| EPS (Diluted) | $0.73 |
| Shares Outstanding (Basic) | 412.00M |
| Shares Outstanding (Diluted) | 417.90M |
Key Highlights
- 1Stryker reported a 17% increase in net sales for Q2 2008 to $1.71 billion and a 16% increase for the first half to $3.35 billion, driven by strong performance across both Orthopaedic Implants and MedSurg Equipment segments.
- 2International sales showed significant growth, increasing by 25% in Q2 and 21% in the first half on a reported basis, highlighting successful global market penetration.
- 3Net earnings from continuing operations saw substantial growth, up 27% in Q2 to $305.8 million and 24% in the first half to $596.3 million.
- 4Diluted Earnings Per Share (EPS) from continuing operations increased to $0.73 in Q2 and $1.43 for the first half, reflecting improved profitability.
- 5The company's outlook remains optimistic, with a projection for 2008 diluted EPS to reach approximately $2.88, a 22% increase.
- 6Despite a challenging market for certain auction-rate securities (ARS) investments, the company stated it has the ability and intent to hold these until recovery of fair value, and expects no impact on its ability to fund operations.
- 7The company continues to invest in research and development, though spending as a percentage of sales decreased in the current periods due to a focus on quality initiatives and a normalization of spending levels.